Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Eisai to use Forma’s DOS technology for drug discovery

Executive Summary

Forma Therapeutics Inc. (small-molecule drug discovery in cancer) has granted Eisai Co. Ltd.’s US operation Eisai Inc. a nonexclusive license to use its Diversity Oriented Synthesis (DOS) chemical compound library and high-throughput cell screening platform for discovery and identification of potential drug candidates against intractable targets.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies